MediWound Ltd. (NASDAQ:MDWD) Receives $33.50 Consensus PT from Analysts

Shares of MediWound Ltd. (NASDAQ:MDWD) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $33.50.

A number of analysts have issued reports on MDWD shares. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target (up from $31.00) on shares of MediWound in a report on Friday, November 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a research report on Wednesday, October 8th. Wall Street Zen raised MediWound from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Finally, Zacks Research upgraded shares of MediWound from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th.

Institutional Investors Weigh In On MediWound

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. increased its position in MediWound by 17.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 22,468 shares of the biopharmaceutical company’s stock worth $349,000 after buying an additional 3,343 shares during the period. Corebridge Financial Inc. grew its position in shares of MediWound by 17.1% during the first quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 665 shares during the last quarter. Silverberg Bernstein Capital Management LLC grew its position in shares of MediWound by 41.9% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 147,535 shares of the biopharmaceutical company’s stock worth $2,858,000 after acquiring an additional 43,591 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of MediWound by 2,255.2% in the 1st quarter. Deutsche Bank AG now owns 6,312 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 6,044 shares during the period. Finally, Nuveen LLC purchased a new stake in MediWound in the 1st quarter valued at $168,000. 46.83% of the stock is currently owned by institutional investors and hedge funds.

MediWound Stock Down 0.5%

NASDAQ MDWD opened at $18.79 on Wednesday. MediWound has a 52 week low of $14.14 and a 52 week high of $22.50. The stock has a market capitalization of $208.38 million, a PE ratio of -9.89 and a beta of 0.07. The firm has a 50 day moving average of $18.32 and a two-hundred day moving average of $18.50.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Thursday, November 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.57. The business had revenue of $5.43 million for the quarter, compared to analyst estimates of $6.56 million. MediWound had a negative net margin of 98.43% and a negative return on equity of 62.11%. On average, equities research analysts expect that MediWound will post -2.66 earnings per share for the current fiscal year.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.